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Abstract
Background: There is growing evidence that microglia are key players in the pathological process of amyotrophic
lateral sclerosis (ALS). It is suggested that microglia have a dual role in motoneurone degeneration through the
release of both neuroprotective and neurotoxic factors.
Results: To identify candidate genes that may be involved in ALS pathology we have analysed at early symptomatic
age (P90), the molecular signature of microglia from the lumbar region of the spinal cord of hSOD1G93A mice, the most
widely used animal model of ALS. We first identified unique hSOD1G93A microglia transcriptomic profile that, in addition
to more classical processes such as chemotaxis and immune response, pointed toward the potential involvement of the
tumour suppressor gene breast cancer susceptibility gene 1 (Brca1). Secondly, comparison with our previous data on
hSOD1G93A motoneurone gene profile substantiated the putative contribution of Brca1 in ALS. Finally, we established
that Brca1 protein is specifically expressed in human spinal microglia and is up-regulated in ALS patients.
Conclusions: Overall, our data provide new insights into the pathogenic concept of a non-cell-autonomous disease and
the involvement of microglia in ALS. Importantly, the identification of Brca1 as a novel microglial marker and as possible
contributor in both human and animal model of ALS may represent a valid therapeutic target. Moreover, our data points
toward novel research strategies such as investigating the role of oncogenic proteins in neurodegenerative diseases.
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Background
Amyotrophic lateral sclerosis (ALS) is characterised by
selective motoneurones degeneration in the spinal cord,
brainstem and motor cortex leading to progressive
muscle weakness, atrophy and paralysis. Approximately
90 % of ALS patients are sporadic whilst 10 % are
familial cases with genetic mutations in SOD1 (Cu/Zn
superoxide dismutase 1), FUS (fused in sarcoma),
TARDBP (also known as TDP-43) and C9ORF72,
among others [1]. Transgenic mice over-expressing the
human mutated gene for SOD1 develop an adult-onset
paralysis that closely recapitulates human ALS [2].
Recent studies have established that ALS is a complex
multi-factorial disease that involves several cellular
partners including glial cells [3].
Microglia, the resident immune cells of the central
nervous system (CNS), when activated, release pro-
and anti-inflammatory cytokines and chemokines that
are generally associated with M1 and M2 phenotypes
[4, 5]. Microglia have a dual role in ALS with an
early protective effect on motoneurones but also a
detrimental effect due to the secretion of neurotoxic
factors [6]. It is hypothesised that progressive moto-
neurone death results from the combination of intrinsic
motoneurones vulnerability and toxicity from neigh-
bouring cells such as microglia [6]. In ALS patients and
animal models, there is a clear microglia activation [3],
in particular we have shown an early involvement of
microglia in hSOD1G93A mice [7]. Understanding the
contribution of microglia to motoneurone degeneration
is of high priority. One means of analysing the role of a
cell population in a process network is to study gene
expression alterations in this given population. In
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addition, an integrative comparison of the specific molecu-
lar signatures of several cellular partners is necessary to
decipher the crosstalk between these cells. We have previ-
ously identified gene dysregulation in pure motoneurones
from the lumbar spinal cord of hSOD1G93A mice [8] and
two other mouse models of motoneurone disease [9]. We
revealed a unique motoneurone gene expression profile
characterised by an absence of dysregulation of genes
associated with cell death and a massive up-regulation of
genes involved in cell growth [8].
Growing evidence points toward mitochondrial dys-
function and oxidative DNA damage in ALS [10]. De-
fence mechanisms, including SOD, counteract excessive
accumulation of reactive oxygen species, however in
ALS, cellular antioxidant defences are insufficient lead-
ing to damage of nucleic acids, proteins and lipids [11].
Inherited mutations in breast cancer susceptibility gene
1 (Brca1), a well-known tumour suppressor implicated
in familial breast and ovarian cancers, is one of the best
defined risk factor for development of breast and ovarian
cancer. Brca1 plays important roles in a broad spectrum
of functions including transcription regulation, cell cycle
checkpoint activation, apoptosis, chromosomal remod-
elling, ubiquitination and DNA repair [12]. The role of
Brca1 in each of these processes remains to be fully
understood but it is hypothesized that it act as a scaf-
fold for the formation of complexes with a wide range
of proteins [13]. This ability of Brca1 to interact with
different proteins may underlie its involvement in a
variety of cellular processes [13]. Brca1 also exerts a
protective role against oxidative stress via up-regulation
of antioxidant genes and maintenance of the redox
balance through up-regulating the expression of heat
shock protein HSP27 [14, 15].
In breast cancer, Brca1 cellular localisation as well as
the significance of its altered localisation, is still a matter
of debate. It had been recently shown that in normal
breast, Brca1 nuclear expression is strong and uniform
in parenchymal cells whereas in malignant cells its ex-
pression is reduced if not absent from the nucleus and
is, in some cases, observed in the cytoplasm [16]. Inter-
estingly, altered expression of Brca1 was associated with
poor prognosis and shortened survival. In the adult ro-
dent CNS, the presence of Brca1 is detected only in neu-
rons [17] whereas a high Brca1 expression is observed in
embryonic [17, 18] and adult neural stem cells and is in-
volved in cell proliferation [18].
Here we identify putative Brca1 involvement in ALS
via hSOD1G93A microglia gene profiling and comparisons
to our previous transcriptomic findings in hSOD1G93A
motoneurones. We then demonstrated that Brca1 is a
novel marker of human microglia and is up-regulated in
ALS patients.
Results
Transcriptomic analysis of FACS isolated microglia from
control and hSOD1G93A lumber spinal cord
We have previously described early microglial distur-
bances in hSOD1G93A male mice reflected at P90 by a
heterogeneous Iba1+ microglial distribution with higher
density within the grey matter in hSOD1G93A mice as
compared to control [7, 19]. Since activated microglia/
macrophages exhibit increased CD11b expression, we
carried out CD11b immunostaining (Fig. 1a & b).
CD11b-positive microglia displayed enlarged somata
with short and thick processes that are typical of a re-
active phenotype and were predominantly found in
hSOD1G93A mice (Fig. 1b). To further analyse tran-
scriptomic modification specifically in microglia, we
isolated microglia of hSOD1G93A and control litter-
mate males at early symptomatic age (P90) from the
lumbar spinal cord (L1-L5) that corresponds to the onset
of degeneration. Microglia were isolated by fluorescence-
activated cell sorting (FACS) using CD11b (Fig. 1c–e). We
observed a 1.65-fold increase in the total number of
CD11b+ microglia in hSOD1G93A versus controls (26
350; n = 15 in hSOD1G93A and 15 900; n = 26 in con-
trol; Fig. 1c & d). RNA extracted from FACS purified
microglia was of high quality (Fig. 1f ) and microarrays
analysis revealed 630 dysregulated genes (260 down-
regulated and 370 up-regulated, Additional file 1:
Table S1).
Cross-talk between microglia and motoneurones
We had previously identified dysregulated genes in
hSOD1G93A motoneuronse during disease progression
[8, 9]. To unravel potential molecular cross-talk between
microglia and motoneurones, we performed a compara-
tive analysis of gene dysregulation in both cell popula-
tions. Comparison of dysregulated genes at P90 between
motoneurones (102 genes) and microglia (668 genes) re-
vealed 19 common genes (Additional file 2: Figure S1A).
Process network rankings were clearly different in the
commonly dysregulated genes (in motoneurones and
microglia) and uniquely dysregulated genes. Antigen
presentation was classified first in the common group,
whilst cytoskeleton and cytoplasmic microtubules genes
were top ranked in motoneurones only set (Additional
file 3: Table S2A). Similarly, cellular processes analysis
ranked first immune response and antigen presentation
in the common group whereas response to stress,
regulation of immune response, system development
and wounding response were the top 4 ranked pro-
cesses in motoneurones only group (Additional file 3:
Table S2B). Signalling and metabolic pathway analysis
revealed immune response and cytoskeleton remodel-
ling as first ranked in the commonly and motoneurone
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only dysregulated genes, respectively (Additional file 3:
Table S2C).
We have previously shown that microglial reactivity
precedes neuronal death in hSOD1G93A mice [7]; to
seek for potential modifications in microglia that could
trigger motoneurone death, we compared dysregulated
genes at P90 in microglia and P120 in motoneurones.
Our previous microarrays analysis of microdissected
motoneurones at the end stage of the disease (P120)
showed no dysregulation of genes associated with cell
death [8], this most likely reflects that dissected moto-
neurones were at an early demise stage. Indeed, we se-
lected motoneurones that had an identifiable nucleus
and a diameter of at least 25 μm, picking a sub-
population of neurones that may resist degeneration.
Three hundred twenty genes were uniquely dysregu-
lated in hSOD1G93A motoneurones; 603 uniquely
dysregulated in hSOD1G93A microglia; 65 genes were
Fig. 1 FACS analysis of CD11b+ microglia in control and hSOD1G93A mice from the lumbar segment of the spinal cords at 90 days of age.
Microglia were sorted by flow cytometry using the microglia marker CD11b. a Confocal images of CD11b expression in spinal cord microglia
from control at 90 day of age and (b) from transgenic hSOD1G93A mice at early symptomatic age. Scale bars (a & b): 50 μm. c–d Representative
flow cytometry analysis dot plot displaying microglia profiles. c Control and (d) hSOD1G93A spinal microglia at P90. In both (c) control and
(d) hSOD1G93A surrounded areas, designed as “P4”, correspond to the labelled cells. e Negative control (without CD11b labelling). The X-axis
represents the intensity of fluorescence and the Y axis the size of the cells. f RNA quality isolated from FACSed microglia
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common (Additional file 2: Figure S1B). Clear differences
were highlighted not only between the genes that were
commonly and uniquely dysregulated but also in the rank-
ing as compared to the previous analysis (microglia and
motoneurones at P90, Additional file 4: Table S3). Particu-
larly, inflammation and immune response were ranked
top in motoneurones (Additional file 4: Table S3A).
Interestingly, signalling and metabolic pathway analysis
revealed the involvement of heme metabolism and DNA
damage in both motoneurones and microglia (Additional
file 4: Table S3C).
Unique transcriptomic profiles of hSOD1G93A microglia
To identify processes and pathways modified in hSOD1G93A
microglia, we carried out gene ontology enrichment
and network analysis (Additional file 5: Table S4A–C;
Fig. 2). Process network analysis ranked as first chemo-
taxis (Additional file 5: Table S4A, Fig. 2a) with 23 dys-
regulated transcripts out of 137 annotated genes in this
process (17 %, p = 2.1E-08) (Additional file 5: Table
S4A). Out of the 18 most significantly dysregulated
genes, 4 were down-regulated with a maximum of 2-
fold whereas 14 were up-regulated (Fig. 2a). The gene
coding for osteopontin (SPP1) presents a 16.8-fold in-
crease (Additional file 1: Table S1). Regulation of angio-
genesis (ranked 8th, Additional file 5: Table S4A,
Fig. 2e) displayed 22 dysregulated genes (223 genes in
this process, 9.8 %, p = 7.3E-04), with 16 being up-
regulated. Inflammation network was also dysregulated
in hSOD1G93A microglia (ranked 9th, 9 % of the annotated
genes in this process, p = 1.4E-04, Additional file 5: Table
S4A, Fig. 2d) with 14 up-regulated genes (including a 12.6
fold increase for IGF-1, Fig. 2d). GO cellular processes
analysis ranked immune response as first (61/1505 genes,
4 %, p = 1.3E-18, Additional file 5: Table S4B, Fig. 2b).
Out of the 38 most significantly dysregulated genes 5
were down-regulated with a maximum of 2.97-fold de-
crease for the gene coding for alpha-synuclein, whereas
33 were up-regulated. Genes coding for CCL5 (5.1-fold
change (FC)) and CXCL13 (5.7-FC) were the most up-
regulated (Additional file 1: Table S1). Regulation of
blood coagulation was ranked 3rd (50/665 genes, 7.5 %,
p = 1.8E-09, Additional file 5: Table S4B, Fig. 2f ).
Amongst the 29 most significantly dysregulated genes 8
were down-regulated and 21 were up-regulated. Hypoxia
was the 4th dysregulated cellular processes (31/416 genes,
7.45 %, p = 8.3E-09, Additional file 5: Table S4B). Out of
the 20 most significantly dysregulated genes 4 were
down-regulated and 16 were up-regulated (Fig. 2c).
Breast cancer 1 (Brca1) pathway is dysregulated in
hSOD1G93A mice
Pathways map analysis ranked as the third position
DNA damage and specifically the involvement of Brca1
as a transcription regulator (Additional file 5: Table S4C,
Figs. 2g and 3). Indeed, in hSOD1G93A microglia (7/30
genes, 23 %; p = 1.6E-05, Additional file 5: Table S4C)
were dysregulated in the canonical Brca1 pathway.
GADD45α and SP3 transcription factor were down-
regulated with FC of 2.6 and 1.9, respectively. Genes
coding for p21 (2.18-FC), PCNA (1.85-FC), STAT1
(1.9-FC), c-Myc (1.8-FC) and Brca1 (1.76-FC) were up-
regulated (Additional file 1: Table S1 and Fig. 2g). Con-
comitant dysregulation of these genes clearly pointed
toward a potential involvement of Brca1 as a transcrip-
tion regulator (Fig. 2g and red and blue thermometers
labelled in Fig. 3). Interestingly, even if Brca1 tran-
script itself was not dysregulated in motoneurones, 4
genes that are involved in Brca1 pathway were also up-
regulated in hSOD1G93A motoneurones namely p21:
7.88-FC; GADD45α: 5.19-FC; Rb protein: 2.44-FC and
ATF-1: 2.38-FC, (Fig. 2h and red thermometers la-
belled 2 in Fig. 3). To confirm microarray findings, we
carried out quantitative real-time polymerase chain
reaction (qPCR) in pure populations of hSOD1G93A
and wild type microglia and assessed the expression
profiles of all candidate genes involved in Brca1 path-
way (Additional file 6: Figure S2). In addition, we have
also included microglial samples at 60 days of age to
assess the potential involvement of microglial Brca1 at
the initial stages of the disease progression in
hSOD1G93A mice (Additional file 6: Figure S2A). Our
qPCR results showed no significant dysregulation of
the genes involved in Brca1 pathway at 60 days of age
(Additional file 6: Figure S2A). However, at 90 days of
age, and similarly to our microarrays results, we found
up-regulation of Brca1, Cdkn1a, Myc, Pcna and Stat1
as well as down-regulation of Gadd45a and Sp3 in
hSOD1G93A microglia (Additional file 6: Figure S2B).
It is important to note that dysregulation in Cdkn1a,
Myc, Pcna, Stat1, Gadd45a and Sp3 transcripts may
also be involved in other signalling pathways. These
findings confirm Brca1 involvement in hSOD1G93A
microglia is specifically triggered at 90 days of age
when the pronounced microgliosis becomes evident.
Brca1 protein is expressed in human microglia and is
up-regulated in ALS patients
To investigate Brca1 protein expression in human
microglia, we performed dual immunofluorescence la-
belling using Brca1 and CD11b antibodies (Fig. 4). Brca1
staining in human control samples revealed ramified
microglial population throughout the spinal cord dis-
playing small cell bodies with long and thin processes
(Fig. 4a & d) that co-localised with CD11b-positive
microglia (Fig. 4b & e, c & f). Similarly, single immuno-
peroxidase detection of Brca1 revealed microglial profile
that were identical to Iba1 (the most commonly used
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Fig. 2 Enrichment and network analysis of dysregulated gene in pure hSOD1G93A microglia at 90 days of age. Categories networks and gene
ontology processes that are most significantly modified in hSOD1G93A microglia at 90 days as compared to control microglia. In each category,
the most dysregulated genes are presented
Noristani et al. Molecular Neurodegeneration  (2015) 10:34 Page 5 of 13
microglia marker) using adjacent human spinal cord sec-
tions (Fig. 5). Ramified microglia were evident in control
cases following both Brca1 and Iba1 immunoperoxidase
labelling (Fig. 5a–d). On the other hand, Brca1-positive
microglia displayed enlarged cell bodies with short/thick
processes in ALS cases similar to Iba1 immunostaining
(Fig. 5e–h).
Finally, to determine Brca1 dysregulation in ALS, we
quantified Brca1 immunoreactivity between the control
and ALS spinal cords (Fig. 6). Brca1 expression was
more evident in ALS compared to control cases (Fig. 6a
& b, c & d). Quantitative analysis revealed a significant
78.2 % increase in Brca1 intensity within the white mat-
ter in ALS samples compared to controls (26.4 vs 47.1,
p = 0.015; Fig. 6e). Within the grey matter, we observed a
32.8 % increase in Brca1 intensity in ALS samples com-
pared to controls, however data variations in control
samples kept them from attaining statistical significance
(49.7 vs 66, p = 0.0545; Fig. 6f ).
Discussion
Non-cell autonomous toxicity plays a major role in ALS
[20] but microglia participation is dual and complex.
Microglia reactivity over the course of the disease may
be characterised by a continuum of activation states
from a M2 neuroprotective state to a deleterious M1
state. In culture, microglia have, at disease onset, a M2
phenotype whereas they are typified by a M1 phenotype
Fig. 3 Brca1 pathway is involved in microglia from hSOD1G93A mice. Gene ontology pathway map analyses of dysregulated genes either in
hSOD1G93A microglia at symptomatic age (P90) or in hSOD1G93A motoneurones at the end stage of the disease (P120) demonstrate the involvement of
Brca1 pathway. Thermometers indicate gene dysregulation (red: up-regulated; blue: down-regulated, thermometer levels correspond to the
level of dysregulation). Thermometers with number 1 represent gene dysregulation in hSOD1G93A microglia and number 2 in hSOD1G93A
motoneurones. Interactions between objects: green (positive or activation); red (negative or inhibition); grey (unspecified). B Binding (physical
interaction between molecules), TR Transcription regulation (physical binding of a transcription factor to target gene’s promoter), +p Phosphorylation
(protein activity is altered via addition of a phosphate group). Binding protein Transcription factor Kinase Generic enzyme
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at disease end-stage [21]. Comparison of our data to
previous studies [21, 22] reveals an up-regulation of five
M2 priming genes (Clec7a, Igf1, Mmp12, Spp1 and
Lgals3) and a down-regulation of Retnla and F13a1.
Interestingly, four M1 priming genes are up-regulated
CD86, Tnfα, Bcl2a1a and Cxcl10, whilst growth arrest
and DNA-damage-inducible alpha gene (Gadd45gip1) is
down-regulated. A previous study has reported the gene-
expression profile of isolated microglia in hSOD1G93A
mice and shown that potentially neuroprotective and
neurotoxic factors are induced concurrently during dis-
ease progression [23]. The authors have analysed micro-
glia from the entire spinal cord whereas we have restricted
our investigations to the lumbar segment where onset of
degeneration occurs. We report that hSOD1G93A micro-
glia from the lumbar region of the spinal cord over-
express progranulin, Igf1 and osteopontin, all potential
neurotrophic factors, and thus confirmed findings from a
previous study [23]. Interestingly, we had previously iden-
tified in pure motoneurones of two mouse models of
motoneurone disease (hSOD1G93A and pmn) an increase
in IGFBP. Also, an IGFBP that binds to IGF-1 and IGF-2
(nephroblastoma over-expressed gene) was up-regulated
at all disease stages in hSOD1G93A mice [8] and IGFBP4
mRNA was induced at pre-symptomatic age in pmn
mice [9]. We also confirmed the up-regulation of po-
tential neurotoxic factors (including Mmp12, tnf-α and
interferon-induced protein with tetratricopeptide repeats)
[23]. However, we did not confirm the dysregulation of
the genes coding for IL-1β, IL-α, IL-10, Ifnar 1 and
Ifnar 2 as well as Nox2 at P90. It had been shown that
delayed forelimb motor impairment in ALS mice may
be partially explained by augmented protective re-
sponses in the cervical spinal cords [24], thus gene ex-
pression profile of lumbar hSOD1G93A microglia is
potentially more homogenous and is more likely to re-
flect a pathological gene profile than microglia taken
from the entire spinal cord. Together, these data con-
firm that microglia activation states are best charac-
terised as a continuum of M2 and M1 states [21] with a
M2 phenotype at early stage of the disease that evolves
into a M1 phenotype at disease end-stage.
An unexpected finding was the up-regulation in
hSOD1G93A microglia of Brca1 with a 1.76 fold. Using
in silico comparison with data from Chiu et al. [23],
we found that Brca1 was also deregulated in their
study and presented a steady increased with 2.78 and
3.08 fold changes at P100 and P130, respectively. In
our study, Brca1 involvement was substantiated by the
concomitant dysregulation of a number of other genes.
As previously stated, Igf1 was robustly up-regulated in
hSOD1G93A microglia; a complex interplay between
Brca1 and IGF signalling pathways had been reported
in familial cancer, in particular through the conver-
gence of Brca1-mediated tumour protective pathways
and IGF1 receptors-mediated cell survival [25, 26].
This simultaneous up-regulation may represent a po-
tential neuroprotective phenotype of microglia in ALS
Fig. 4 Microglial expression of Brca1 in human spinal cords. Confocal micrographs displaying Brca1 (a, d), CD11b (b, e) and dual Brca1/CD11b
expression (c, f) expression by microglia within the human spinal cord. Brca1 labelled microglia displayed typical ramified morphology with small
cell bodies and large and thin processes that completely colocalised with CD11b-positive microglia (c & f). Scale bars (a–c): 50 μm; (d–f): 10 μm
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Fig. 5 Microglial Iba1 and Brca1 expression within adjacent human control and ALS spinal cord. Brightfield micrographs indicating Iba1 and Brca1
expression within adjacent sections of control (a–d) and ALS (e–h) spinal cords. Both Ibal and Brca1-labelled microglia displayed typical ramified
morphology in the control spinal cords with small cell bodies and large and thin processes (c & d). Microglial morphology displayed similar features
following Iba1 (a & c) and Brca1 (b & d) immuno staining. In ALS spinal cords, Ibal and Brca1-labelled microglia displayed both ramified and activated
microglia with enlarged cell bodies and short and thick processes (g & h). Microglial morphology were similar using Iba1 (e & g) or Brca1 (f & h)
immuno staining. Scale bars (a–h): 50 μm
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at early stage. Converging elements toward the involve-
ment of Brca1 was also pointed through the dysregula-
tion of genes linked to Brca1 and belonging to the
DNA damage pathway (Fig. 3). Indeed, GADD45 was
down-regulated in hSOD1G93A microglia (P90) and up-
regulated in motoneurones (P120) and it had been
demonstrated that Brca1 can modulate GADD45 that
in turn mediates DNA repair mechanisms and regulates
growth arrest [15]. Importantly, we found that the gene
coding for cyclin-dependent kinase inhibitor 1A (p21)
was up-regulated both in hSOD1G93A microglia (P90)
and motoneurones (P120). Indeed, p21 is a downstream
target of p53 and regulates several processes such as
DNA repair, cell cycle arrest, cell differentiation and
apoptosis. Through its antioxidant effects, p21 also pro-
tects cells from oxidative damage in vitro and in vivo
[15]. Activation of microglial cells and acquisition of
deleterious M1 state is associated with an increased
generation of reactive oxygen species (ROS) [27] that
is likely to participate in motoneurone demise. Polar-
isation of microglia/macrophages to pro- and anti-
inflammatory states is driven by cytokines and other
factors such as ROS within the tissue microenviron-
ment [28]. While the functional role of deregulated
Brca1 pathway in microglia remains to be determined,
one hypothesis is that it may represent an attempt to
counteract the detrimental effects of ROS and reflect
an antioxidative defence mechanism through modula-
tion of microglia polarisation.
Brca1 is implicated in a broad spectrum of functions;
it regulates transcription and cell cycle progression, it
is also involved in function that preserve genomic sta-
bility such as DNA repair pathways [29] and protection
against oxidative damage to DNA. Many of these func-
tions have been associated with CNS development but
also with neurodegenerative diseases and in particular
Fig. 6 Up-regulation of microglial Brca1 expression in human ALS spinal cords. Brightfield micrographs displaying Brca1 expression within the
spinal cords of control (a & c) and ALS cases (b & d). Bar graphs showing the increase in Brca1 intensity within the white (e) and grey (f) matters
of the spinal cord in ALS compared to control cases. Bars represent mean ± SEM (n = 5 for ALS and 14 for controls). *p < 0.05. Scale bar
(a–d): 100 μm
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with ALS. Brca1 is required for normal cerebral cortex
size development [30] by preventing apoptosis [31].
Using a neural progenitor-specific driver to delete
Brca1, Pao et al. demonstrated an important role of
Brca1 in apoptotic and centrosomal functions in neur-
onal progenitors that may underlie DNA damage and
brain size during development [31]. Brca1 is also asso-
ciated with lack of spinal cord neural tube closure in
spina bifida meningomyelocele [32, 33]. Moreover,
Brca1-deficient embryos presented disorganised neuro-
epithelium associated with rapid proliferation and
enhanced cell death [32].
De-regulation in Brca1 expression had been reported
in Alzheimer’s [34, 35] and Huntington’s diseases [36].
Even though motor neuron diseases are not typical para-
neoplastic syndromes, association with breast cancer
had been regularly reported [37–41]. Moreover, there
are occasional reports on improvement of motor neuron
syndrome after cancer treatment [42–44].
Conclusion
Here we identify putative Brca1 involvement in ALS via
hSOD1G93A microglia gene profiling and comparisons to
our previous transcriptomic findings in hSOD1G93A
motoneurones. Nevertheless, mRNA up-regulation of
Brca1 in hSOD1G93A microglia could be simply anec-
dotal if it were restricted to a mouse model of ALS. This
is not the case since we demonstrated that Brca1 protein
is specifically expressed by human microglia and is sig-
nificantly up-regulated in ALS patients.
These results substantiate that microglia are key non-
cell autonomous players in the disease. Thus, the identi-
fication of the putative Brca1 involvement in a mouse
model and human ALS provides new insights into the




Transgenic mice carrying the G93A human SOD1 muta-
tion, B6SJL-Tg (SOD1-G93A)1Gur/J (ALS mice, high copy
number) were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA) and bred on a B6SJL background.
Transgenic mice were housed in controlled conditions
(hygrometry, temperature and 12 h light/dark cycle).
Ninety days old (P90, symptomatic) males were used
for transcriptomic analysis and immunohistochemistry.
Litter-matching between groups were done. We carried
out all animal experiments in accordance with the guide-
lines approved by the French Ministry of Agriculture and
following the European Council directive (2010/63/UE).
We minimised the number and suffering of animals.
Flow cytometry sorting of spinal cord microglia from
SODG93A and control littermate mice
Mice were deeply anesthetised with tribromoethanol
(500 mg/kg) and intracardially perfused with cold RNAse-
free 0.1 M phosphate base saline (PBS, Invitrogen,
Carlsbad, USA); spinal cords were dissected. Only the
lumbar (L1 - L5) segment was used and dissociated in
750 μl PBS, 100 μl trypsin 13 mg/ml, 100 μl hyaluroni-
dase 7 mg/ml, 50 μl kinurenic acid 4 mg/ml (Sigma
Aldrich, Saint Louis, USA) and 20 μl DNAseI 10 mg/ml
(Roche, Rotkreuz, Switzerland) for 30 min at 37 °C.
Finally, gentle mechanic dissociation was carried out by
pipetting. Cell suspension was sieved on a 40 μm cell
strainer (BD Biosciences, Franklin Lakes, USA). To
eliminate myelin, cells were re-suspended in PBS-25 %
sucrose and centrifuged for 20 min at 750 g. Cells were
incubated for 20 min on ice in the primary antibody
CD11b-APC 1/100 in PBS (BD biosciences, Franklin
Lakes, USA) that specifically labels microglia. Cells
were washed with cold PBS and re-suspended in PBS
7-AAD 2 μg/ml (Sigma Aldrich). Cells were sorted with
a FACS ARIA (BD Biosciences, Franklin Lakes, USA),
equipped with a 488 nm Laser Sapphire 488–20. Size
threshold, morphology and 7-AAD were used to
eliminate cellular debris and dead cells.
Microarray analysis of gene transcripts
Our data comply with the “Minimal Information About
Microarray Experiment (MIAME)” guidelines. Total
RNA was isolated using RNeasy Mini Kit, (Qiagen,
Maryland, USA) including DNAse treatment to remove
potential genomic DNA contamination. We tested the
quality of the starting RNA and of the amplified cRNA
(Agilent 2100 bioanalyzer, RNA 6000 Pico LabChip, Palo
Alto, USA) and proceeded only if the RNA quality was
satisfactory. A criterion was a cut point for RNA integ-
rity number (RIN) at 7 [45]. Fifty nanograms of RNA
per chip were hybridized (three chips per condition)
following a T7-based double amplification procedure.
Hybridization targets were obtained following a double
amplification procedure according to the protocol devel-
oped by Affymetrix (GeneChip® Eukaryotic Small Sample
Target Labeling Assay Version II, Affymetrix, Santa
Clara, USA) and previously used [8, 9]. A hybridization
mixture containing 5.5 μg of biotinylated cRNA was
generated. The biotinylated cRNA was hybridized to
Affymetrix GeneChip® MOE 430 2.0. Three chips per
group (wild type and hSOD1G93A) were hybridized, each
corresponding to microglia from at least six pooled
mice. Chips were visualised on a 3000 gene scanner
(Affymetrix, Santa Clara, USA). We selected the differ-
entially expressed transcripts using the Affymetrix
software MAS 5.0 and carried out pair-wise compari-
son analyses where each of the mutant samples was
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compared to each of their respective control samples. This
analysis is based on the Mann–Whitney pair-wise com-
parison test and allows the ranking of the results by
concordance as well as the calculation of significance
(p value) of each identified gene expression [46, 47]. A
gene must exhibit 50 % or more of the “present” calls
in all samples to be considered “expressed” and has two
or more “present” calls among the three sets of
samples. Fold differences were calculated as the ratio
between the average values within each condition. Sig-
nal values and detection calls (present or absent) for all
samples were determined using Affymetrix MAS5.0.
Based on power analysis, we had selected a cut off
threshold of 1.75 (p (α) 0.05, β 0.80) to identify tran-
scripts that are differentially expressed between the
controls and hSOD1G93A mutant mice. Statistics: t-test
with un-equal variance. Pathway analysis was done with
MetaCore (Thomson Reuters).
Quantitative real-time polymerase chain reaction
Candidate genes involved in Brca1 pathway were vali-
dated using qPCR. Similar to microarray, total RNA was
extracted as described above from CD11-positive micro-
glia isolated using FACS and used as a template in real
time PCR. At least two animals were used for each
analysis. To assess the involvement of microglia Brca1 at
initial stages of the disease progression, we carried out
qPCR at 60 and 90 days of age in hSOD1G93A and wild
type mice. One round of amplification was done follow-
ing the first cycle (first cDNA and cRNA synthesis) of
the Affymetrix double amplification procedure before
undertaking reverse transcription with random hexamers
(Superscript II, Invitrogen, Carlsbad, CA). Real time
PCR using Syber Green PCR Master Mix and Abi Prism
SDS 7900 HT (Applied Biosystems, Foster City, CA) was
done according to the manufacturer’s protocol. All
amplicons were designed within the 3′ end of the cDNA
using Primer Express Software 2.0 (Applied Biosystems,
Foster City, CA) and when possible, overlapped exon-
exon junctions. For the sequences of the primers, see
Additional file 7: Table S5. All samples were analysed in
triplicate and the values were normalised to four refer-
ence genes mitochondrial ribosomal protein S9 (RPS9),
TATA box binding protein (TBP), actin β and eukaryotic
translation elongation factor 1 (EEF1).
Human spinal cord samples
Human low thoracic and lumbar (T11-L5) spinal
cords were obtained from 14 controls (males and fe-
males; 23 to 74 years of age; mean age: 52.4 years) and
five ALS patients (males and females; 66 to 79 years of
age; mean age: 71 years) from the Kantonsspital St.
Gallen Fachbereichsleiter Muskelzentrum/ALS clinic
under the approval of the Swiss legislation and from
the New York Brain Bank–Taub Institute, Columbia
University (NYBB), New York, USA. All donors had
given their written consent for the autopsy and we
followed the Declaration of Helsinki.
Immunohistochemistry
Mice were anesthetised with tribromoethanol (500 mg/kg)
and perfused intracardially with cold PBS followed by
cold 4 % paraformaldehyde (PFA, Sigma Aldrich).
Spinal cords were removed and post fixed for 2 h in
4 % PFA. Samples were cryoprotected in sucrose 30 %,
included in Tissue Teck (Sakura, Alphen aan den Rijn,
The Netherlands), frozen and kept at −80 °C until
processing.
For mice, free floating spinal cord transverse sections
(20 μm) were washed twice in PBS (5 min), treated for
30 min in PBS containing lysine (20 mM, pH 7.2) and
for 15 min in 1 % H2O2. Sections were blocked for 1 h
with PBS containing bovine serum albumin (BSA, 1 %,
Sigma Aldrich) and Triton X-100 (0.1 %, Fisher Scien-
tific, Illkirch, France) and then incubated 48 h at 4 °C
with CD11b (1/200, Developmental Studies Hybridoma
Bank, Iowa, USA) primary antibody. Alexa-conjugated
594 secondary antibody was used (1/1000; Molecular
Probes, Eugene, OR, USA).
For human spinal cord 22 μm-thick cryosections of
lumbar and lower thoracic segments were collected
on super frost plus slides and were processed as de-
scribed above. For dual fluorescence labelling, sections
were placed in a cocktail of rat anti CD11b (1/100,
Hybridoma Bank, University of Iowa, USA) and rabbit
anti-Brca1 (1/100, Santa Cruz Biotechnology, Dallas,
USA) primary antibodies for 48 h at 4 °C. Sections were
washed in 0.1 M PBS followed by incubation in corre-
sponding secondary antibodies conjugated to Alexa 488
and 594 (1/1000; Molecular Probes, Eugene, OR, USA).
For peroxidase labelling, sections were placed for 48 h at
4 °C in either rabbit anti Iba1 (macrophage/microglia-
specific calcium-binding protein) (1/1000, Wako Pure
Chemical Industries, Osaka, Japan) or rabbit anti-Brca1
(1/100, Santa Cruz Biotechnology, Dallas, USA) primary
antibodies. Spinal cord sections were then incubated in
donkey anti-rabbit (1/500, Jackson Immunoresearch,
Carlsbad, USA) antibody for 2 h at 4 °C. Sections were
then washed in TRIS buffer and enzymatic revelation
was done with nickel enhanced DAB and H2O2 0.1 % as
a substrate. Sections were then dehydrated in ascending
concentration of ethanol and finally xylene. Coverslips
were applied using Entellan (Merck KGaA, Darmstadt,
Germany).
Morphometric bright field photographs had been ob-
tained and analysed using NanoZoomer RS slide scanner
(NanoZoomer Digital Pathology System and NDP view
software, Hamamatsu, Japan). For immunofluorescence
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images, we used laser scanning inverted confocal mi-
croscopy (Leica SP5, Mannheim, Germany). Laser in-
tensity and detector sensitivity settings were kept
constant for all image acquisitions within a given
experiment. Brca1 staining intensity measurement was
done by measuring their optical density (OD) using
ImageJ (National Institutes of Health, USA), as de-
scribed previously [48]. For each given sample we
analysed at least three 22-μm-thick section with
330 μm distance from each other. Statistics: un-paired
t-test done with GraphPad Prism version 5.03 (Graph-
Pad software, CA, USA). Significance was accepted at
p ≤ 0.05. Results are expressed as mean ± S.E.M.
Additional files
Additional file 1: Table S1. Database of differential expression
comparison of hSOD1G93A microglia microarray data relative to control
microglia at 90 days of age. We list information for each dysregulated
genes in hSOD1G93A microglia as compared to control microglia. With
both the p-value and the step-up p-value that is the false discovery rate
(FDR) analogue of the p-value. Three chips were used per condition (wild
type and SOD1G93A) with microglia from lumbar spinal cord of at least six
pooled mice.
Additional file 2: Figure S1. Comparison of gene dysregulation in
microglia and motoneurones. (A) Venn diagrams showing that 19 genes
are commonly dysregulated in microglia and motoneurones at symptomatic
age (P90). (B) Comparison of dysregulated genes in microglia at P90 and
motoneurones at disease end stage shows that 65 genes are commonly
dysregulated, 603 genes are uniquely dysregulated in hSOD1G93A microglia
and 320 uniquely in hSOD1G93A motoneurones. Three chips were used per
condition (wild type and SOD1G93A) with microglia from lumbar spinal cord
of at least six pooled mice.
Additional file 3: Table S2. Comparison of gene dysregulation in both
microglia and motoneurones at symptomatic age (P90) and in motoneurone
only (P90) using gene ontology enrichment and network analysis. In all tables
the top scored categories have the lowest p-value. Table S2A: Process
networks ranking. Table S2B: Gene ontology processes ranking and
Table S2C: Pathway maps ranking.
Additional file 4: Table S3. Comparison of gene dysregulation in
microglia at symptomatic age (P90) and in motoneurone at the end
stage of the disease (P120) using gene ontology enrichment and
network analysis. In all tables the top scored categories have the lowest
p-value. Table S3A: Process networks ranking. Table S3B: Gene ontology
processes ranking and Table S3C: Pathway maps ranking.
Additional file 5: Table S4. Gene ontology enrichment and network
analysis of gene dysregulation in microglia at symptomatic age (P90).
In all tables the top scored categories have the lowest p-value. Table
S4A: Process networks. Table S4B: Gene ontology processes and Table
S4C: Pathway maps. Percentage of dysregulated genes corresponds to
the ratio of dysregulated genes in our data out of annotated genes in
the given category (Gene Ontology).
Additional file 6: Figure S2. Quantitative real-time polymerase chain
reaction (qPCR) validation of microarray findings related to candidate
genes involved in Brca1 pathway. To confirm the microarray results,
the seven identified genes involved in Brca1 pathway were analysed
by real time qPCR. Bar graphs showing up-regulation of Brca1, Cdkn1a,
Myc, Pcna and Stat1 as well as down-regulation of Gadd45a and Sp3
in hSOD1G93A microglia at 90 (B) but not 60 days (A) as compared
to control microglia. For each sample, real time PCR was done in
triplicate.
Additional file 7: Table S5. Candidate genes involved in Brca1
pathway selected for qPCR to validate the microarray data.
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